Quantcast

Industry news that matters to you.  Learn more

Meso Scale Discovery Launches New V-PLEX Assays for Th17 Research

Meso Scale Discovery, a division of Meso Scale Diagnostics, LLC. (MSD), recently launched V-PLEX® immunoassays validated for the detection of the biomarkers IL-17A, IL-21, IL-22, IL-23, IL-27, and MIP-3α in human cell culture supernatants, serum, plasma, and urine.

Serum micoRNAs May Serve as Biomarkers for Multiple Sclerosis

MicroRNAs are small RNA molecules that influence basic cellular processes and have been proposed as biomarkers for the diagnosis, progression and treatment of multiple sclerosis. In a new study conducted at the Ann Romney Center of Neurologic Diseases at Brigham and Women’s Hospital, researchers have found that serum microRNAs are linked to MRI findings in the brain and spinal cord in patients with MS. These findings suggest that microRNAs could serve as promising biomarkers for monitoring the progression of MS and could help to identify distinct underlying disease processes, such as inflammation and tissue destruction.

Abcodia Offers Access to its Unique Longitudinal Serum Biobank to Advance Biomarker R&D for Haematological Cancers

Abcodia recently announced an initiative to license access to serum samples from its unique longitudinal serum biobank for use in discovery and validation of biomarkers for haematological cancers. This unparalleled resource, believed to be the largest longitudinal collection of its kind, can substantially reduce the time to market and cost of R&D.

Berg and Medical University of South Carolina Announce First of Its Kind Collaboration to Discover Lupus Biomarker

Berg and the Medical University of South Carolina recently announced a strategic partnership, designed to identify new therapeutic pathways and potential biomarkers to treat Lupus, the autoimmune disease affecting one in every 2,000 people and one in every 250 young African American women.

ARRAYit Technology Used By Researchers at NIH For Important Discovery

ARRAYit Corporation (OTCQB: ARYC) reports today that researchers at the National Institutes of Health (NIH), National Cancer Institute (NCI) and Northeastern University have used the ARRAYit Microarray Platform to discover biomarkers important in the treatment of prostate cancer.